Sign In
Buy KVUE
$16.83
-0.490 (-2.83%)
At Close: Jun 03, 2026
Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
03:44pm, Thursday, 20'th Jul 2023
J&J owns nearly 90% of Kenvue shares and plans to reduce its stake in the company through an exchange offer that could launch "as early as the coming days."
Is Johnson & Johnson Giving Up on Kenvue (KVUE) Stock?
02:36pm, Thursday, 20'th Jul 2023
One of the more interesting moves in today's market comes from recent spinoff Kenvue (NYSE: KVUE ). Currently, shares of KVUE stock are down around 3% in today's session, as the company reported ear
Johnson & Johnson Rips Off the Kenvue Band-Aid
12:06pm, Thursday, 20'th Jul 2023
A surprisingly early distribution and a stretched valuation hit J&J's consumer health arm hard.
Stock movers July 20, 2022: Johnson & Johnson, Kenvue, and Abbott Labs
11:38am, Thursday, 20'th Jul 2023
Johnson & Johnson, Kenvue, and Abbott Labs posted second quarter results that topped analyst estimates. Yahoo Finance Live anchors break down the market reaction to the report.
J&J spinoff Kenvue CEO on first full quarterly earnings results since IPO
11:34am, Thursday, 20'th Jul 2023
Thibaut Mongon, Kenvue CEO, joins 'Squawk on the Street' to discuss the company's quarterly earnings results, what Mongon is seeing from the consumer, and much more.
Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO
07:32am, Thursday, 20'th Jul 2023
J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff's business for the time being.
Tylenol, Benadryl parent Kenvue tops earnings expectations, amid strength in pain care, cold and flu product demand
06:32am, Thursday, 20'th Jul 2023
Tylenol, Benadryl and Listerine brands parent Kenvue Inc. KVUE, +0.77% reported Thursday second-quarter profit and revenue that beat expectations, provided an upbeat full-year outlook and initiated a
Kenvue quarterly sales rise on strong demand for self-care products
06:23am, Thursday, 20'th Jul 2023
Kenvue on Thursday posted a rise in quarterly sales thanks to strong demand for its self-care and skincare brands such as Tylenol and Neutrogena.
3 Healthcare Stocks to Buy as the Market Gets Defensive
12:33am, Tuesday, 18'th Jul 2023
With so much concern about the Federal Reserve and its decision-making implications for forward market trends, investors may do well targeting healthcare stocks. Fundamentally, the underlying sector r
IPO Market Showing Signs Of Life, Drawing Second-Half Optimism On Wall Street
02:15am, Friday, 14'th Jul 2023
The last 18 months have been like an ice age for investment bankers brokering deals and young business owners looking to tap extra capital. Several successful recent IPOs may foster green shoots for f
Like shoppers, IPO investors are demanding discounts and showing price sensitivity
12:17pm, Friday, 30'th Jun 2023
IPO investors, much like shoppers in the current inflationary environment, are demanding clear discounts and demonstrating sensitivity to price and valuations, according to Renaissance Capital.
7 Up-and-Coming Stocks to Buy for the Next Decade
04:49pm, Thursday, 29'th Jun 2023
In arguably most cases involving expert financial advice, you will encounter guidance toward established enterprises, not up-and-coming stocks to buy. While the latter category certainly dials up the
Kenvue to Announce Second Quarter 2023 Results on July 20, 2023
04:30pm, Tuesday, 06'th Jun 2023
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) announced financial results for the second quarter ending July 2, 2023, will be released before market open July 20, 2023.
1 Ultra-Elite Dividend Stock to Buy Hand Over Fist in June
07:36am, Sunday, 04'th Jun 2023
Johnson & Johnson offers a higher dividend yield. It backs that payout with an elite financial profile.
Kenvue's stock hits fresh post-IPO lows as Tylenol parent company receives tepid reviews from analysts
03:27pm, Tuesday, 30'th May 2023
Shares of Kenvue Inc. plumbed new lows after Wall Street analysts started coverage of the consumer household-brands company and Johnson & Johnson spinoff with halfhearted ratings, saying bullish funda
